Elsevier

Clinica Chimica Acta

Volume 152, Issues 1–2, 31 October 1985, Pages 115-122
Clinica Chimica Acta

Bile acid therapies applied to patients suffering from cerebrotendinous xanthomatosis

https://doi.org/10.1016/0009-8981(85)90182-2Get rights and content

Abstract

Patients suffering from cerebrotendinous xanthomatosis, an inborn error of metabolism in bile acid synthesis, were given oral treatment with chenodeoxycholic acid, ursodeoxycholic acid, cholic acid and taurocholic acid. The effectiveness of the different therapies was evaluated by measuring the urinary excretion of 5β-cholestane-3α, 7α,12α,23,25-pentol, which should decrease, when the administered bile acid is able to suppress endogenous bile acid synthesis. From the results it is concluded that chenodeoxycholic acid and cholic acid activate the bile acid negative feedback mechanism, contrary to ursodeoxycholic acid and taurine conjugated cholic acid. Either cholic acid or chenodeoxycholic acid are the therapies of choice for the treatment of cerebrotendinous xanthomatosis. For various reasons the use of cholic acid is especially recommended.

References (20)

There are more references available in the full text version of this article.

Cited by (40)

  • Cataract

    2022, Clinical Ophthalmic Genetics and Genomics
  • Lysosomal Storage Disorders

    2020, Emery and Rimoin’s Principles and Practice of Medical Genetics and Genomics: Metabolic Disorders
  • Bile Acids and Bile Flow: New Functions of Old Molecules

    2017, Zakim and Boyer's Hepatology: A Textbook of Liver Disease
View all citing articles on Scopus
View full text